CLADRIM 10MG – Composition, Uses and Medicine Enquiries
Product Overview
CLADRIM 10MG is listed as a prescription product containing Cladribine 10MG, marketed in the source catalogue by Fresenius Kabi India Pvt Ltd.
It belongs to the anticancer; purine nucleoside analog class and may be prescribed for hairy cell leukemia and other selected specialist indications.
Its active ingredient disrupts DNA synthesis in susceptible abnormal white blood cells.
The exact manufacturer pack, formulation, approved indication and administration schedule must be checked before treatment or publication. A qualified clinician should assess suitability, interactions, contraindications and monitoring requirements.
Severe marrow suppression and infection risks require blood count monitoring.
Composition and Strength
The supplied product information identifies the following composition:
| Active Ingredient | Strength |
|---|---|
| Cladribine | 10MG |
Product Name: CLADRIM 10MG
Generic Name: Cladribine
Brand Name: CLADRIM 10MG
Strength: 10MG
Listed Marketer: Fresenius Kabi India Pvt Ltd
The composition and strength should be verified against the original manufacturer-labelled packaging before publication or any medicine enquiry.
Therapeutic Category and Indication
CLADRIM 10MG belongs to the anticancer category and is classified as a purine nucleoside analog.
It may be prescribed for hairy cell leukemia and other selected specialist indications.
Cladribine works by disrupting DNA synthesis in susceptible abnormal white blood cells.
Treatment choice depends on the confirmed diagnosis, previous treatment, organ function and other medicines. The benefit-risk balance, approved use and monitoring plan must be determined by the treating specialist.
Severe marrow suppression and infection risks require blood count monitoring.
Administration Information
The supplied product information identifies intravenous administration by oncology professionals under an approved protocol.
Administration must follow the treating clinician’s instructions and the approved product label.
Patients should not independently adjust the dose, skip safety monitoring or switch formulations without medical advice.
The exact administration schedule must be verified against the approved product information.
Product Presentation and Availability
The product enquiry can be made using the following details:
- Product Name: CLADRIM 10MG
- Generic Name: Cladribine
- Strength: 10MG
- Company Name: Fresenius Kabi India Pvt Ltd
- Therapeutic Category: Anticancer
- Medicine Class: Purine Nucleoside Analog
- Indication: Hairy cell leukemia and other selected specialist indications
- Administration: Intravenous administration by oncology professionals under an approved protocol
The exact dosage form, pack size, batch, storage, expiry and product-specific presentation require verification from original manufacturer packaging and an authorised provider.
Product details and supply eligibility may vary by country. A product listing does not confirm current stock or availability.
Prescription and Patient Safety
CLADRIM 10MG is listed as a prescription anticancer medicine and requires specialist supervision.
Treatment suitability, contraindications, interactions and monitoring requirements must be evaluated by a qualified oncology specialist.
Severe marrow suppression and infection risks require blood count monitoring.
Patients should follow the approved product label and the treating oncology team’s instructions. The medicine should only be administered according to an approved clinical protocol.
Medicine Enquiry Coordination Through Medinglobal
Medinglobal is a healthcare coordination platform. It can receive medicine information requests and, where legally permissible, connect patients or institutions with appropriately authorised independent pharmaceutical providers.
Medinglobal does not itself sell, dispense, manufacture or export medicines.
Product availability, lawful supply, prescription validation, commercial terms and destination requirements must be verified by the independent provider. Submitting an enquiry does not guarantee fulfilment.
How to Submit a CLADRIM 10MG Enquiry
To help identify the requested product, include the following details:
- Product name: CLADRIM 10MG.
- Generic name: Cladribine.
- Required strength: 10MG.
- Required formulation and quantity.
- Destination country.
- Valid prescription or institutional documents, where required.
Medinglobal may coordinate an introduction to a suitably authorised provider. The provider independently verifies product details, regulatory eligibility and any transaction.
Frequently Asked Questions
What is CLADRIM 10MG used for?
CLADRIM 10MG is associated with hairy cell leukemia and other selected specialist indications. The treating prescriber confirms the approved use.
What is the composition of CLADRIM 10MG?
The supplied catalogue lists Cladribine 10MG as its active ingredient. The composition should be verified against the original product packaging.
How is CLADRIM 10MG administered?
The supplied information identifies intravenous administration by oncology professionals under an approved protocol.
Which company is listed for CLADRIM 10MG?
Fresenius Kabi India Pvt Ltd is listed as the marketer in the supplied product information.
Does CLADRIM 10MG require specialist supervision?
Yes. Treatment requires specialist supervision. Severe marrow suppression and infection risks require blood count monitoring.
Can Medinglobal supply CLADRIM 10MG directly?
No. Medinglobal coordinates medicine enquiries with independent authorised providers where legally permissible.


Reviews
There are no reviews yet.